#Bayer has won #FDAapproval for #oralHER2inhibitor #Hyrnuo as a #firstlinetreatment for advanced HER2-mutant non-small cell lung cancer (#NSCLC), just a year after it was cleared as a second-line option.

pharmaphorum.com/news/bayer-m...